Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127953 | PMC |
| http://dx.doi.org/10.1148/radiol.242837 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Calcifications Affect Pathologic Complete Response and MRI Prediction after Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer.
Radiology
September 2025
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.
Background The optimal surgical management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer with calcifications remains controversial, particularly when pathologic complete response (pCR) is suspected. Purpose To identify factors associated with pCR after neoadjuvant chemotherapy in patients with HER2-positive breast cancer and assess whether calcifications affect the performance of radiologic complete response (rCR) at MRI for predicting pCR. Materials and Methods This retrospective study included patients with HER2-positive breast cancer who received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab and underwent surgery between January 2021 and October 2023.
View Article and Find Full Text PDFEarly Detection of Lung Metastases in Breast Cancer Using YOLOv10 and Transfer Learning: A Diagnostic Accuracy Study.
Med Sci Monit
September 2025
Department of Radiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.
BACKGROUND This study used CT imaging analyzed with deep learning techniques to assess the diagnostic accuracy of lung metastasis detection in patients with breast cancer. The aim of the research was to create and verify a system for detecting malignant and metastatic lung lesions that uses YOLOv10 and transfer learning. MATERIAL AND METHODS From January 2023 to 2024, CT scans of 16 patients with breast cancer who had confirmed lung metastases were gathered retrospectively from Erzincan Mengücek Gazi Training and Research Hospital.
View Article and Find Full Text PDFCECT-based simplified scoring model for differentiating low-risk thymomas from hyper-attenuating thymic cysts: A STARD compliant article.
Medicine (Baltimore)
September 2025
Hebei Key Laboratory of Molecular Oncology, Tangshan, Hebei Province, China.
This retrospective study aims to evaluate the effectiveness of a simplified scoring model utilizing contrast-enhanced computed tomography (CECT) in distinguishing low-risk thymomas (LRTs) from thymic cysts in patients with anterior mediastinal hyper-attenuating nodules. A total of 32 patients of LRTs and 40 patients of hyper-attenuating thymic cysts who underwent chest biphasic CECT preoperatively from January 2015 to December 2022 were included. The traditional CT imaging features and clinical features of each patient were analyzed.
View Article and Find Full Text PDFValidation of uPath HER2 dual-colour dual in-situ hybridisation image analysis tool for HER2/neu testing in breast cancer.
J Clin Pathol
September 2025
Department of Pathology, Tata Memorial Center, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India
Aims: gene is amplified in 15%-20% of invasive breast cancers (IBCs), serving as critical prognostic and predictive marker. -targeted therapies have improved outcomes for -positive patients, highlighting the importance of accurate assessment. Immunohistochemistry is commonly used for screening overexpression, with equivocal cases reflex tested using in situ hybridisation (ISH) methods like fluorescence (FISH) or dual-colour dual ISH (D-DISH).
View Article and Find Full Text PDFMetastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study.
JMIR Res Protoc
September 2025
Department of Health Services Research & Administration, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.
View Article and Find Full Text PDF